<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Medical Journal of the Islamic Republic Of Iran</title>
<title_fa>مجله پزشکی جمهوری اسلامی ایران</title_fa>
<short_title>Med J Islam Repub Iran</short_title>
<subject>Medical Sciences</subject>
<web_url>http://mjiri.iums.ac.ir</web_url>
<journal_hbi_system_id>2</journal_hbi_system_id>
<journal_hbi_system_user>journal2</journal_hbi_system_user>
<journal_id_issn>1016-1430</journal_id_issn>
<journal_id_issn_online>2251-6840</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.18869/mjiri</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1395</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2017</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<volume>31</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Comparison of the effect of lithium plus quetiapine with lithium plus risperidone in children and adolescents with bipolar I disorder: a randomized clinical trial</title>
	<subject_fa>Psychiatry</subject_fa>
	<subject>Psychiatry</subject>
	<content_type_fa>Original Research</content_type_fa>
	<content_type>Original Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;p&gt;&lt;strong&gt;Background:&lt;/strong&gt; In the treatment of bipolar disorder in youths, often more than one medication should be prescribed. In the current&lt;br&gt;
study, we compared the efficacy and tolerability of the combination of lithium and quetiapine with lithium and risperidone in the&lt;br&gt;
treatment of manic or mixed episodes in children and adolescents.&lt;br&gt;
&lt;strong&gt;Methods:&lt;/strong&gt; Thirty patients (aged 10-18 years) who were hospitalized for a manic or mixed episode were recruited from consecutive&lt;br&gt;
inpatient admissions to the Child and Adolescent Psychiatric Unit at Razi Psychiatric Hospital (University of Social Welfare and Rehabilitation&lt;br&gt;
Sciences, Tehran, Iran) from June 2012 to September. They were randomly treated with lithium (with the usual dose to&lt;br&gt;
achieve blood levels 0.8-1) and quetiapine (400-600 mg per day) or risperidone (0.5-6 mg per day). The primary outcome measure&lt;br&gt;
with respect to efficacy was the mean decrease in Young Mania Rating Scale (YMRS) score. Side effects were also assessed. The independent&lt;br&gt;
t test and two-factor repeated measure analysis of variance (ANOVA) was used for data analysis. P-value of less than 0.05&lt;br&gt;
was considered statistically significant.&lt;br&gt;
&lt;strong&gt;Results:&lt;/strong&gt; The reduction in YMRS scores was similar in both groups. The remission rate (YMRS &lt;12) in the group treated with quetiapine&lt;br&gt;
was 80% and with risperidone was 66.6%; the difference was not significant. The most common side effect was sedation in both&lt;br&gt;
groups. Extrapyramidal side effects were observed only with risperidone. Both drugs caused increased levels of prolactin.&lt;br&gt;
&lt;strong&gt;Conclusion:&lt;/strong&gt; Both protocols were effective. Quetiapine in combination with lithium in manic or mixed episodes of bipolar I disorder&lt;br&gt;
in children and adolescents was not superior to lithium and risperidone, but was associated with fewer complications.&lt;/p&gt;
</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Children, Adolescents, Bipolar Disorder, Quetiapine, Risperidone, Lithium</keyword>
	<start_page>90</start_page>
	<end_page>95</end_page>
	<web_url>http://mjiri.iums.ac.ir/browse.php?a_code=A-10-1578-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Nastaran </first_name>
	<middle_name></middle_name>
	<last_name>Habibi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>200319475328460031224</code>
	<orcid>200319475328460031224</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Nasrin </first_name>
	<middle_name></middle_name>
	<last_name>Dodangi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>200319475328460031225</code>
	<orcid>200319475328460031225</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Ali </first_name>
	<middle_name></middle_name>
	<last_name>Nazeri</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>200319475328460031226</code>
	<orcid>200319475328460031226</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
